CapsoVision — Third Quarter 2026 Earnings Summary

CapsoVision reported third-quarter 2026 revenue of $3.6 million, a slight increase from $3.5 million in the same period of 2025, while net loss narrowed to $7.3 million from $7.9 million. The company received FDA clearance for its AI Highlights tool in September 2026 and launched it commercially in November, alongside completing enrollment for its CapsoCam Colon study with an expected FDA submission by year-end. Financial results reflected a gross margin decline to 49% due to higher material costs and inventory charges, though operating expenses decreased to $9.1 million. To support its operations and development pipeline, CapsoVision raised approximately $19.5 million in net proceeds through a registered direct offering and an at-the-market program during the quarter.